Biota Initiates Phase 2 Trial of Laninamivir Octanoate for the Treatment of Influenza in Adults
June 11, 2013 at 16:52 PM EDT
Biota Pharmaceuticals (Nasdaq: BOTA) (the "Company") today announced that it has commenced dosing in a multi-national, randomized, double blind, placebo controlled, parallel arm Phase 2 clinical trial of laninamivir octanoate, a long-acting neuraminidase inhibitor. The trial, referred to as "IGLOO", will compare the safety and efficacy of 40 mg and
